The goal of this clinical trial is to reduce heavy drinking and enhance medication for opioid use disorder (MOUD) outcomes in individuals receiving MOUD. The main questions it aims to answer are: * Does the brief, digitally-enhanced, virtual psychotherapeutic intervention, called Managing Physical Reactions to Overwhelming Emotions (IMPROVE), impact daily alcohol use and MOUD adherence? * Does the intervention change self-report and physiological responses to intolerance to uncertainty and anxiety sensitivity? Researchers will compare IMPROVE to a control intervention (health education treatment) to see if IMPROVE impacts daily alcohol use and MOUD adherence. Participants will: * Complete a baseline electroencephalography (EEG) and self-report questionnaires. * Complete three one-hour intervention sessions (IMPROVE or control) each one week a part. * Complete a post-intervention EEG and self-report questionnaires. * Complete five ecological momentary assessment (EMA) surveys a day for 21 days. * Complete self-report questionnaires one-month after their last intervention session.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
80
Participants may be randomized to IMPROVE. IMPROVE is a three session virtual intervention delivered by research clinicians and augmented by a mobile application. The treatment is designed to target and reduce distress contributing to heavy alcohol use during medication for opioid use disorder treatment.
Participants may be randomized to HET. HET is an active control intervention that is equally intensive as IMPROVE It includes three virtual sessions and a mobile application. HET is designed to target healthy lifestyle behaviors such as diet and sleep.
Ohio State University
Columbus, Ohio, United States
RECRUITINGAlcohol Use
Changes in proportion of heavy drinking days and drinks per drinking day following the intervention.
Time frame: Change from baseline to post-treatment (week 4)
Startle eyeblink potentiation during unpredictable threat
Startle eyeblink potentiation will be collected during the No-, Predictable-, Unpredictable -Threat (NPU) startle paradigm. Startle is a cross-species index of aversive reactivity. Startle during unpredictable threat is an objective indicator of response to uncertain stress.
Time frame: Change from baseline to post-treatment (week 4)
Self-reported Intolerance of Uncertainty
The Intolerance of Uncertainty- Short Form is a gold-standard self-report assessment. Subscale scores on the measure range from 7-35 for 'prospective intolerance of uncertainty' and 5-25 for 'inhibitory intolerance of uncertainty', with higher scores indicating greater intolerance of uncertainty.
Time frame: Change from baseline to post-treatment (week 4)
Late positive potential when viewing anxiety sensitivity evoking images
The late positive potential will be collected from the emotional picture paradigm. The late positive potential captures emotional reactivity. Emotional reactivity to a battery of anxiety sensitivity-evoking images is an objective indicator of response to bodily anxiety sensations.
Time frame: Change from baseline to post-treatment (week 4)
Self-reported Anxiety Sensitivity
The Anxiety Sensitivity Index-3 scale is a gold standard self-report assessment. Scores range from 0 to 72 where higher scores indicate higher anxiety sensitivity.
Time frame: Change from baseline to post-treatment (week 4)
Medication Adherence
Changes in proportion of days compliant with medication for opioid use disorder.
Time frame: Change from baseline to post-treatment (week 4)
Distress-related alcohol use
Participants will report their psychological distress and subsequent alcohol use behavior.
Time frame: Assessed multiple times a day for 21 days
Daily alcohol craving
Participants will report their alcohol craving throughout each day.
Time frame: Assessed multiple times a day for 21 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.